# ResistanceBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/resistancebio

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.resistance.bio
- Latest round: Seed (Jul 20, 2022)
- Investors on record: 6

## About

Based in California, US, and founded by Nick Goldner (CEO), and Chris Bulow (COO), ResistenceBio, a portfolio company of Alumni Ventures, is a biotechnology company that identifies and creates novel therapeutics for cancer patients who are resistant to clinical treatment.

The firm employs its proprietary drug and target discovery platform, ResCu, that predicts the resistance of cancerous cells during clinical treatments to identify resistance target networks and resistance biomarkers that aid pharma companies in developing cancer treatments. The platform helps to determine the best drug for a cancer type, and the best patient population for treatment and identifies novel resistance targets for new therapies.

## Funding rounds

- Seed, Jul 20, 2022 — Alumni Ventures Group, Liquid 2 Ventures, NFX, Cantos Ventures, Pioneer Fund, Formic Ventures

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed
- Liquid 2 Ventures (https://capitalatlas.ai/funds/liquid-2-ventures) — Seed
- NFX (https://capitalatlas.ai/funds/nfx) — Seed
- Cantos Ventures (https://capitalatlas.ai/funds/cantos-ventures) — Seed
- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed
- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Seed